

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026177 A1

- (51) International Patent Classification⁷: A61F 2/06, B24C 11/00
- (21) International Application Number: PCT/EP2003/010542
- (22) International Filing Date: 22 September 2003 (22.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 02021067.0 20 September 2002 (20.09.2002) EP
- (71) Applicant (*for all designated States except US*): ABBOTT LABORATORIES VASCULAR ENTERPRISES LIMITED [IE/IE]; Earlsfort Center, Terrace, Dublin 2 (IE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): SCHÖMIG, Albert [DE/DE]; Böcklinstr. 40, 80638 München (DE). KASTRATI, Adnan [AL/DE]; Volpininstr. 78, 80638 München (DE). VON OEPEN, Randolph [DE/DE]; Gartenstr. 42, 72074 Tübingen (DE).
- (74) Agent: VOSSIUS & PARTNER; Siebertsrasse 4, 81675 München (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- *with international search report*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: STENT WITH ROUGH SURFACE AND ITS MANUFACTURE



05017.TIF
688-550-256.tif

(57) **Abstract:** A stent is provided wherein at least an outer surface portion is roughened to a predetermined extent and wherein a drug or a therapeutic agent can be applied to said surface. This results in an improved stent, which can be manufactured at low costs and which can further avoid thrombus formation and a stenosis.

WO 2004/026177 A1

Stent with rough surface and its manufacture

The present invention relates generally to stents which are implantable or deployable in a vascular or endoluminal location within the body of a patient to maintain the lumen open and unoccluded at that location, and in particular to improvements in stents.

First of all, stents are widely used for numerous applications where the stent is placed in the lumen of a patient and expanded. Said stents may be used in coronary or other vasculature as well as within the urinary tract, the bial tract and the intestinal tract among other body passageways and conduits.

Commonly, stents are cylindrical members which are expanded from reduced diameters to enlarged diameters. Frequently, such stents are placed on a balloon catheter with the stent in a reduced diameter state. To prevent that the balloon is damaged because of sharp corners and burrs on the surface of the stent and further to avoid thrombus formation, stents are highly polished. This is done for example by sandblasting the surface to remove said imperfections and polishing the stent afterwards to get a smooth surface. Unfortunately, the balloon catheter mounted stent can be dislodged from the uninflated balloon as a result of the navigation through the vessel of the body to the preselected site for deployment because of the highly polished surface. Furthermore, the polished and smooth surface used to avoid thrombus formation has the disadvantage, that endothelial cells have difficulties to ingrow the stent which can result in that restenosis occurs.

In the prior art, some stents are sandblasted on their interior surface to improve stent retention on the balloon.

In US-A-6 254 631 B1 a stent is disclosed, wherein the exterior surface of the stent is polished such that a smooth surface finish is achieved. The interior surface having a rough

surface finish is rougher than the surface finish of the exterior surface to enhance the friction between the stent and the balloon.

Further in US-A-6 217 607 B1 a stent is disclosed which is provided with a first layer of noble metal. Further a second outermost layer is provided which is composed of a ceramic like metal such as iridium oxide or titanium nitride. The second layer is formed with a rough surface to provide an increased friction factor and retention on a balloon during advancement of the stent delivery system through the vessel.

In WO 99/07308 a stent is disclosed wherein a portion of a stent supporting structure is encapsulated with a thin flexible coating made of a polymer which can be used as a carrier for supporting therapeutic agents and drugs. Furthermore, the supporting structure, preferably only the portion which is not encapsulated by the thin flexible coating, is further processed to form a porous exterior surface. Said porous exterior surface renders the exposed portions of the supporting structure, such as the proximal and distal ends more biocompatible by promoting tissue in-growth while reducing the formation of blood clots.

Said stents of the prior art have the disadvantage that they are complicated to manufacture and expensive.

The object of the present invention is therefore to provide an improved stent, which can be manufactured at low costs and which can further avoid thrombus formation and a stenosis.

This object is achieved by the features of the claims.

According to the invention a stent is provided comprising at least an outer surface portion which is roughened to a predetermined extent and wherein a drug or a therapeutic agent can be applied to said surface.

This has the advantage, that the stent does not have to be provided with an additional drug deposit e.g. a polymer layer suitable to carry a drug or therapeutic agent. Instead the drug can be applied directly to the rough surface and released over a predetermined time after the stent has been placed in a desired location of a lumen. Furthermore a roughened exterior

surface decrease in-stent restenosis, since cells can attach more easily to said surface than to a smooth one which results in that endothelial ingrowth is accelerated. Intima cells can grow on the rough surface and attach themselves, wherein the endothelialization of the vessel or lumen is promoted. The endothelial cell layer is very smooth and therefore thrombus formation and a stenosis can be avoided.

In a preferred embodiment the drug e.g. Tacrolimus is applied to the rough surface by spraying. This has the advantage, that the application of the drug is effective, simple and inexpensive.

In a further preferred embodiment of the invention imperfections such as e.g. burrs are removed before at least a portion of the surface of the stent is roughened. This has the advantage that the surface can be roughened more uniform which leads to better flow dynamics. Thus less turbulences can occur on the surface which results in a reduction of restenosis.

In a preferred embodiment of the invention the surface is roughened to a predetermined extent by sandblasting. Moreover, sandblasting results in an improvement of the fatigue behaviour. Further the durability of the stent and the surface bonding can be improved. The rough surface also provides an increased surface area for an attachment of a drug or therapeutic agent. Further a stent with a thinner wall with higher radial force and therefore less material can be achieved which also leads to a decrease of restenosis. With sandblasting the surface can be better controlled and produced and further a more uniform and trauma less surface can be achieved.

Furthermore, the use of corundum for sandblasting results in a surface which is technically different from a normal sandblasted surface. It has the advantage that less energy has to be used and/or less time for this finishing sandblasting than for a sandblasting process to remove burrs. Further the sandblasted surface has less depth with regard to the "cavities". Furthermore the chemical behaviour of such a stent is different from commonly known electropolished stents. The surface chemistry is different due to the incorporation of sand particles into the surface. An immediately repassivated surface leads to more chemically stable passive layers than surfaces which have been passivated in equilibrium.

When blasting the surface the resulting lattice imperfections (e.g. vacancy, dislocation) and further possible phase transitions lead to an increased surface energy and thus to a surface which is chemically more reactive. This can lead to a faster chemical running and/or to additional chemical reactions than in the equilibrium.

In a further preferred embodiment the stent is annealed after the surface has been roughened to a predetermined extent to make him more flexible.

The invention will now be described with reference to the figures, in which

figures 1 to 7 show sandblasted exterior and side surfaces of a stent in different resolutions,

figures 8 to 14 show sandblasted interior and side surfaces of a stent in different resolutions,

figure 15 shows a table 1, including a list of samples of stents which are used for studying content and release of a drug applied on their surface,

figure 16 show tables 2 and 3 wherein the results of several samples regarding their content are listed,

figure 17 show tables 4 and 5, wherein samples are studied regarding release of the drug Tacrolimus, and

figure 18 shows a diagram, wherein the release of Tacrolimus of samples with respect to time is shown.

In an embodiment of a stent according to the invention, as shown in figures 1 to 14, the complete surface, i.e. exterior surface, interior surface and side surfaces, is sandblasted by using corundum. It is obvious that the invention is not limited to said embodiment and that also only portions of the surface can be roughened.

In figures 15 to 18 content and release of samples of stents are studied. In this connection normal manufactured stents are compared with stents which are further processed according

to the invention. Based on the examples shown in the figures the improved properties of stents according to the invention can be demonstrated.

Claims :

1. A stent for placement in a body lumen which is expandable from a contracted state to an expanded state, the stent comprising :
 - a) an exterior surface, an interior surface and side surfaces,
 - b) wherein at least a portion of the exterior surface is roughened to a predetermined extent for coating with a drug.
2. A stent according to claim 1, comprising at least a portion of the interior surface which is roughened to a predetermined extent.
3. A stent according to claims 1 or 2, comprising at least a portion of the side surfaces which is roughened to a predetermined extent.
4. A stent according to any of claims 1 to 3, wherein the outer surface and/or the inner surface and/or side surfaces are coated with a drug, preferably Tacrolimus.
5. A stent according to any of claims 1 to 4, wherein said stent comprises a stainless steel.
6. A balloon catheter device for inserting a tubular stent, comprising a stent as defined in any of claims 1 to 5.

7. A method for fabricating a stent for placement in a body lumen, said method comprising the following steps:
 - a) forming a tube which can be employed from a contracted state to an expanded state, said stent having an exterior surface, an interior surface and side surfaces,
 - b) roughening of at least a portion of the exterior surface to a predetermined extent,
 - c) coating of said surface with a drug.
8. A method according to claim 7, wherein at least a portion of the interior surface is roughened to a predetermined extent.
9. A method according to claims 7 or 8, wherein at least a portion of the side surfaces is roughened to a predetermined extent.
10. A method according to any of claims 7 to 9, wherein the surface is roughened to a predetermined extent by sandblasting.
11. A method according to any of claims 7 to 10, including an additional step d) after step a) wherein imperfections such as sharp edges and burrs are removed from the surface of the tube.
12. A method according to claim 11, wherein the imperfections are removed by burring.
13. A method according to claim 11 or 12, wherein the imperfections are removed by electropolishing.
14. A method according to any of claims 7 to 13, wherein the imperfections are removed by sandblasting.
15. A method according to any of claims 10 to 14, wherein sand is used for sandblasting.
16. A method according to any of claims 10 to 15, wherein glass beads are used for sandblasting.

17. A method according to any of claims 10 to 16, wherein corundum is used for sandblasting.
18. A method according to any of claims 7 to 17, wherein the drug is Tacrolimus.
19. A method according to any of claims 7 to 18, wherein the drug is applied by spraying on the roughened surface.
20. A method according to any of claims 7 to 19, wherein the tube is annealed.




Fig 1

05017.TIF
688-560-256.tif




Fig 2

05018.TIF
688-560-256.tif




Fig 3

05019.TIF
688-560-256.tif




Fig 4

05020.TIF
712-572-256.tif




Fig 5

05021.TIF
688-560-256.tif




Fig 6

05022.TIF
688-560-256.tif




Fig 7

05023.TIF
712-572-256.tif

2/3




Fig 8

05024.TIF
688x680x256 bit




Fig 9

05025.TIF
688x680x256 bit




Fig 10

05026.TIF
688x680x256 bit



Fig 11

05027.TIF
712x672x256 bit




Fig 12

05028.TIF
688x680x256 bit




Fig 13

05029.TIF
688x680x256 bit



Fig 14

05030.TIF
712x672x256 bit

3/3

Figure 15

Lot # 094846
Article # 310S1635
Target dose 230 µg

	shipped	sample #
drug-content-RCC (3)	14.08.02	5971-5979
drug-release-RCC (3)	14.08.02	5980-5982
DMAC-RCC (1)	0	
samples for ageing		
samples for additional tests		

Table 1

result:

= Felder für Einträge

Content - results
Date of content: 16.08.02

Table 2

Sample #	Target Dose [µg/Stent]	Content [µg/Stent]	Content mean [µg/Stent]	STDEV [µg]	CV [%]	Target Deviation [%]
5971		223				
5978	230	189	205	17,0	8,30	-10,7
5979		204				

Figure 16

Table 3

Release only [µg]	% Release of content	Stent only* [µg]	% of content	Release+ Stent [µg]	% of content
99,0	48,2		0,0	99,0	48,2
107,0	52,1		0,0	107,0	52,1
111,0	54,1		0,0	111,0	54,1
105,7	51,5	0,0	0,0	105,7	51,5

*) extraction after release test

Release
CT Lots with new method
(pH6)

Single values [µg Tacrolimus]

Table 4

Wavelength: 210 nm

sample #	0.16	0.5	1	4	6	24	48	72	96
5980	17	19	12	14	6	15	12	3	1
5981	22	18	10	14	7	15	13	6	2
5982	27	18	9	14	6	15	13	7	2
Average	22,0	18,3	10,3	14,0	6,3	15,0	12,7	5,3	1,7

Figure 17


Accumulated values [µg Tacrolimus]

Table 5

1 = < 2 µg

sample #	0.16	0.5	1	4	6	24	48	72	96
5980	17	36	48	62	68	83	95	98	99
5981	22	40	50	64	71	88	99	105	107
5982	27	45	54	68	74	89	102	109	111
Average	22,0	40,3	50,7	64,7	71,0	86,0	98,7	104,0	105,7

Figure 18



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/10542

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/06 B24C11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61F B24C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 199 16 086 A (INFLOW DYNAMICS INC) 14 October 1999 (1999-10-14) column 2, line 9 - line 43; claims 1-3; figures	1-9, 20
X	EP 0 850 604 A (SORIN BIOMEDICA SPA) 1 July 1998 (1998-07-01) column 5, line 38 - line 43; claims 15, 27, 28; figure 4	1, 5
A		4, 6, 7, 10, 15, 16
X	US 6 099 561 A (ALT ECKHARD) 8 August 2000 (2000-08-08) cited in the application column 8, line 61 - line 67; claim 3; figures	1, 4-6
A		7, 20
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 January 2004

Date of mailing of the international search report

22/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Neumann, E

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/EP 03/10542

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 083039 A (ADVANCED CARDIOVASCULAR SYSTEM) 24 October 2002 (2002-10-24) paragraph '0032! - paragraph '0034!; claims 1-5,21,23; figures 1-3 ----	1,4-7, 10,19
P,X	EP 1 254 673 A (INFLOW DYNAMICS INC) 6 November 2002 (2002-11-06) paragraph '0005!; claims; figures paragraph '0017! ----	1,4-7,18
A	US 6 387 123 B1 (JACOBS JAMES M ET AL) 14 May 2002 (2002-05-14) column 5, line 54 -column 6, line 13; claims 1,3 ----	7,11,13, 20
A	WO 99 07308 A (SUNSCOPE INTERNATIONAL) 18 February 1999 (1999-02-18) cited in the application page 12, line 18 - line 22 ----	11,12,14
A	US 6 431 958 B1 (RICHARD JO EUML L ET AL) 13 August 2002 (2002-08-13) column 1, line 53 -column 2, line 4 column 1, line 19 - line 20 -----	14-17

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2-5,7-20

A stent and its manufacturing method

2. Claims: 1,6

A balloon catheter

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/10542

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/10542

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19916086	A	14-10-1999	US 5980566 A	09-11-1999
			DE 19916086 A1	14-10-1999
			US 6099561 A	08-08-2000
			US 6387121 B1	14-05-2002
			WO 9952471 A1	21-10-1999
EP 0850604	A	01-07-1998	IT T0961095 A1	30-06-1998
			AT 232704 T	15-03-2003
			DE 69719161 D1	27-03-2003
			DE 69719161 T2	09-10-2003
			EP 1181903 A2	27-02-2002
			EP 0850604 A2	01-07-1998
			ES 2192649 T3	16-10-2003
			US 2003195613 A1	16-10-2003
			US 6638302 B1	28-10-2003
US 6099561	A	08-08-2000	US 5824045 A	20-10-1998
			US 6217607 B1	17-04-2001
			US 6387121 B1	14-05-2002
			EP 0836839 A2	22-04-1998
			DE 19916086 A1	14-10-1999
WO 02083039	A	24-10-2002	WO 02083039 A1	24-10-2002
EP 1254673	A	06-11-2002	US 2002165607 A1	07-11-2002
			EP 1254673 A1	06-11-2002
			EP 1254674 A1	06-11-2002
US 6387123	B1	14-05-2002	NONE	
WO 9907308	A	18-02-1999	AU 741328 B2	29-11-2001
			AU 9103098 A	01-03-1999
			EP 1003444 A1	31-05-2000
			JP 2001513359 T	04-09-2001
			WO 9907308 A1	18-02-1999
US 6431958	B1	13-08-2002	FR 2775919 A1	17-09-1999
			AU 2734199 A	11-10-1999
			CA 2323499 A1	23-09-1999
			EP 1062074 A1	27-12-2000
			WO 9947307 A1	23-09-1999
			JP 2002506741 T	05-03-2002
			TW 393382 B	11-06-2000
			ZA 9902033 A	27-09-1999